NEWS

WIRES

OTHER

Cell Bio-Systems, Inc.(R) Unveils New Line of Tulip(R) Disposable Plastic Surgery Instruments at Plastic Surgery 2005 Show

Cell Bio-Systems, Inc.® (OTC: CBSI) announced today the release of its new line of disposable cannulas for the plastic surgery market. Four new products, part of a growing line of new instruments, will be unveiled to over 2,000 surgeons at Plastic Surgery 2005 (ASPS), the nation's largest show focusing on education and products related to the plastic surgery industry. Plastic Surgery 2005 is scheduled to occur between September 24th and September 27th, 2005.

"Tulip Disposable Products, and specifically our new Tulip Disposable cannulas, represent a new era in instrumentation and related products for our biggest customer, plastic surgeons," said Marc Pilkington, CEO of Cell Bio-Systems, maker of the Tulip Disposable line of products. "Today's plastic surgeons have greater demands on their time as well as increased regulatory oversight of their industry. Our Tulip Disposable cannulas address the current environment by providing plastic surgeons with disposable cannulas that are cost effective when compared to traditional reusable products, yield better and more efficient outcomes, and are safer for patients."

The new Tulip Disposable cannulas incorporate CellFriendly™ technology, which includes the implementation of certain lubricous coatings that the company believes make surgical procedures less stressful on the patient and easier for the plastic surgeon to use.

"Instruments and products in plastic surgery continue to evolve. Just like plastic replaced glass in the disposable syringe market years ago, our new products give plastic surgeons modern instrumentation options," according to Cell Bio-Systems President and COO, Darin Andersen. "It was important to us to incorporate the Tulip® brand name on these products because plastic surgeons know and trust the brand."

Tulip is a well established brand in re-usable cannulas currently used worldwide in many procedures such as Liposuction, Body Sculpting, Fat Transfer and more. Tulip has a history dating back to the early 1990s when the name was used to describe the original cannulas used to connect to syringes for use in Liposuction and the introduction of the Syringe System now commonly used in related procedures.

"Plastic surgeons and their customers have been anticipating a disposable instrument solution in this market for years," says Andersen. "Our close relationship with Tulip Medical®, the most trusted and well known name in the reusable cannula market, is critical to the launch of this new line."

About Cell Bio-Systems, Inc.

Cell Bio-Systems, Inc. (OTC: CBSI) is a Nevada corporation whose operations are based in San Diego, California. Founded in 2004, Cell Bio-Systems is a Medical Device, Biotechnology Company seeking to manufacture and distribute patented technologies for the Plastic & Cosmetic Surgery, Biopsy, Orthopedic Surgery, Stem Cell Therapy and other Living Tissue markets. Cell Bio-System is the exclusive licensee of patented syringe connection devices which use the worldwide recognized Tulip brand name. Cell Bio-Systems will manufacture, market, and distribute medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets.

This press release contains certain forward-looking information about Cell Bio-Systems, Inc. ("Cell Bio-Systems") which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Cell Bio-Systems, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy, the grade and quantity of minerals in our projects may not be economic, we do not have fee title to our properties, but derive our right through leases and the Mining Law, we are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission, we trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Cell Bio-Systems does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Distributed by Market Wire